The growth
of interventional oncology market is primarily driven by the rising
preference for minimally invasive procedures, expansion of the target patient
population, increasing public-private funding and government support for cancer
research, technological advancements in the field of interventional oncology,
and increasing government investments and funding for interventional oncology
and related cancer research.
[180 Pages Report] The global interventional
oncology market is projected to reach USD 2.9 billion by 2024 from USD 2.0
billion in 2019, at a CAGR of 6.8%.
The study involved four major activities to estimate the current size of
the interventional oncology market. Exhaustive secondary research was done to
collect information on the market and its different subsegments. The next step
was to validate these findings, assumptions, and sizing with industry experts
across the value chain through primary research. Both top-down and bottom-up approaches
were employed to estimate the complete market size.
Market Size Estimation:
A detailed market estimation approach was followed to estimate and validate
the size of the interventional oncology market and other dependent submarkets,
as mentioned above. The key players in the interventional oncology market were
identified through secondary research, and their market shares in the
respective regions were determined through primary and secondary research.
Research methodology includes the study of the annual and quarterly financial
reports of the top market players as well as interviews with industry experts
for key insights (both quantitative and qualitative trends) on the
interventional oncology market.
1. The key
players in the industry and market have been identified through extensive
secondary research
2. The
market generated by leading players has been determined through primary and
secondary research
3. All
percentage shares, splits, and breakdowns have been determined using secondary
sources and verified through primary sources.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=203687164
Key Questions Answered in The Research Report:
1. What
are the growth opportunities related to the adoption of interventional oncology
across major regions in the future?
2. Emerging countries have immense opportunities for the growth and adoption of
interventional oncology procedures. Will this scenario continue in the next
five years?
3. Where will all the advancements in products offered by various companies
take the industry in the mid- to long-term?
4. What are the cancer types that are treated by interventional oncology
procedures? Can these procedures replace surgery?
Recent Industry Developments:
# In 2017, Terumo Corporation (Japan) launched the QuiremSpheres Microspheres in
Europe.
# In 2017, Medtronic PLC (Ireland) launched its OptiSphere embolization spheres
designed for hypervascular tumor embolization in the US.
# In 2016, Ethicon (Johnson and Johnson, US) acquired NeuWave Medical, Inc.
(US), and consequently the NeuWave microwave ablation portfolio with the aim to
expand its product portfolio in the interventional oncology market.
Market Segmentation and Analysis:
Based on product, the interventional oncology market is segmented into
ablation devices, embolization devices, and support devices.
Based on procedure, the global interventional oncology industry is segmented
into thermal tumor ablation, non-thermal tumor ablation, transcatheter arterial
chemoembolization (TACE), transcatheter arterial radioembolization (TARE) or
selective internal radiation therapy (SIRT), and transcatheter arterial
embolization (TAE) or bland embolization.
Based on cancer type, the interventional oncology market is segmented into
liver cancer, kidney cancer, lung cancer, bone cancer, and other cancers
(includes pediatric cancer, prostate cancer, and breast cancer).
Request Sample Report:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=203687164
Key Players:
The
major players operating in the interventional oncology market include BTG plc
(UK), Medtronic (Ireland), Boston Scientific (US), Terumo (Japan), Merit
Medical (US), Sirtex (China), AngioDynamics (US), Ethicon (US), Teleflex (US),
Cook Medical (US), HealthTronics (US), MedWaves Medical (US), Sanarus
(US), IMBiotechnologies (Canada), Trod Medical (US), IceCure Medical (Israel),
Mermaid Medicals (Denmark), Interface Biomaterials BV (Netherlands), Guerbet (France),
ABK Biomedical (Canada), Shape Memory Medical (US), Endo Shape (US), Monteris
Medical (US), Instylla (US), and Trisalus Lifesciences (US), among others.
Medtronic (Ireland)
dominated the global interventional oncology market. The company focuses on
adopting various organic growth strategies like product launches &
approvals and inorganic growth strategies, such as acquisitions and
collaborations, to expand its presence and share in the interventional oncology
market.
